Geodon is a drug owned by Pfizer Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 28, 2025. Details of Geodon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7175855 | Ziprasidone suspension |
May, 2020
(4 years ago) |
Expired
|
| US6150366 | Ziprasidone formulations |
May, 2019
(5 years ago) |
Expired
|
| US6245766 | Method of treating psychiatric conditions |
Dec, 2018
(5 years ago) |
Expired
|
| US5312925 | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Geodon's patents.
Latest Legal Activities on Geodon's Patents
Given below is the list of recent legal activities going on the following patents of Geodon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 04 Jun, 2002 | US6399777 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Jun, 2002 | US6399777 |
| Issue Notification Mailed Critical | 17 May, 2002 | US6399777 |
| Receipt into Pubs | 01 May, 2002 | US6399777 |
| Application Is Considered Ready for Issue Critical | 30 Apr, 2002 | US6399777 |
| Workflow - Drawings Finished | 22 Apr, 2002 | US6399777 |
| Workflow - Drawings Matched with File at Contractor | 22 Apr, 2002 | US6399777 |
| Workflow -Received 85b - Unmatched | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Received Critical | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Verified Critical | 22 Apr, 2002 | US6399777 |
FDA has granted several exclusivities to Geodon. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Geodon, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Geodon.
Exclusivity Information
Geodon holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Geodon's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
US patents provide insights into the exclusivity only within the United States, but Geodon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Geodon's family patents as well as insights into ongoing legal events on those patents.
Geodon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Geodon's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 28, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Geodon Generic API suppliers:
Ziprasidone Hydrochloride is the generic name for the brand Geodon. 9 different companies have already filed for the generic of Geodon, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Geodon's generic
How can I launch a generic of Geodon before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Geodon's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Geodon's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Geodon -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg, 40 mg, 60 mg and 80 mg | 07 Feb, 2005 | 5 | 02 Mar, 2012 | 27 May, 2019 | Eligible |
About Geodon
Geodon is a drug owned by Pfizer Inc. It is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis. Geodon uses Ziprasidone Hydrochloride as an active ingredient. Geodon was launched by Pfizer Inc in 2006.
Approval Date:
Geodon was approved by FDA for market use on 29 March, 2006.
Active Ingredient:
Geodon uses Ziprasidone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Ziprasidone Hydrochloride ingredient
Treatment:
Geodon is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis.
Dosage:
Geodon is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE/ML | SUSPENSION | Discontinued | ORAL |
Geodon is a drug owned by Viatris Specialty Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 28, 2025. Details of Geodon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6150366 | Ziprasidone formulations |
May, 2019
(5 years ago) |
Expired
|
| US6245766 | Method of treating psychiatric conditions |
Dec, 2018
(5 years ago) |
Expired
|
| US5312925 | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Geodon's patents.
Latest Legal Activities on Geodon's Patents
Given below is the list of recent legal activities going on the following patents of Geodon.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Recordation of Patent Grant Mailed Critical | 04 Jun, 2002 | US6399777 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Jun, 2002 | US6399777 |
| Issue Notification Mailed Critical | 17 May, 2002 | US6399777 |
| Receipt into Pubs | 01 May, 2002 | US6399777 |
| Application Is Considered Ready for Issue Critical | 30 Apr, 2002 | US6399777 |
| Workflow - Drawings Finished | 22 Apr, 2002 | US6399777 |
| Workflow - Drawings Matched with File at Contractor | 22 Apr, 2002 | US6399777 |
| Workflow -Received 85b - Unmatched | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Received Critical | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Verified Critical | 22 Apr, 2002 | US6399777 |
FDA has granted several exclusivities to Geodon. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Geodon, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Geodon.
Exclusivity Information
Geodon holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Geodon's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
US patents provide insights into the exclusivity only within the United States, but Geodon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Geodon's family patents as well as insights into ongoing legal events on those patents.
Geodon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Geodon's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 28, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Geodon Generic API suppliers:
Ziprasidone Hydrochloride is the generic name for the brand Geodon. 9 different companies have already filed for the generic of Geodon, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Geodon's generic
How can I launch a generic of Geodon before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Geodon's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Geodon's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Geodon -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg, 40 mg, 60 mg and 80 mg | 07 Feb, 2005 | 5 | 02 Mar, 2012 | 27 May, 2019 | Eligible |
About Geodon
Geodon is a drug owned by Viatris Specialty Llc. It is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis. Geodon uses Ziprasidone Hydrochloride as an active ingredient. Geodon was launched by Viatris in 2001.
Approval Date:
Geodon was approved by FDA for market use on 05 February, 2001.
Active Ingredient:
Geodon uses Ziprasidone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Ziprasidone Hydrochloride ingredient
Treatment:
Geodon is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis.
Dosage:
Geodon is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | CAPSULE | Prescription | ORAL |
| EQ 60MG BASE | CAPSULE | Prescription | ORAL |
| EQ 80MG BASE | CAPSULE | Prescription | ORAL |
| EQ 20MG BASE | CAPSULE | Prescription | ORAL |
Geodon is a drug owned by Viatris Specialty Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 28, 2025. Details of Geodon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6399777 | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) |
Expired
|
| US6232304 | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(7 years ago) |
Expired
|
| US6110918 | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Geodon's patents.
Latest Legal Activities on Geodon's Patents
Given below is the list of recent legal activities going on the following patents of Geodon.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Recordation of Patent Grant Mailed Critical | 04 Jun, 2002 | US6399777 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Jun, 2002 | US6399777 |
| Issue Notification Mailed Critical | 17 May, 2002 | US6399777 |
| Receipt into Pubs | 01 May, 2002 | US6399777 |
| Application Is Considered Ready for Issue Critical | 30 Apr, 2002 | US6399777 |
| Workflow - Drawings Finished | 22 Apr, 2002 | US6399777 |
| Workflow - Drawings Matched with File at Contractor | 22 Apr, 2002 | US6399777 |
| Workflow -Received 85b - Unmatched | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Received Critical | 22 Apr, 2002 | US6399777 |
| Issue Fee Payment Verified Critical | 22 Apr, 2002 | US6399777 |
FDA has granted several exclusivities to Geodon. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Geodon, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Geodon.
Exclusivity Information
Geodon holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Geodon's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
US patents provide insights into the exclusivity only within the United States, but Geodon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Geodon's family patents as well as insights into ongoing legal events on those patents.
Geodon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Geodon's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 28, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Geodon Generic API suppliers:
Ziprasidone Mesylate is the generic name for the brand Geodon. 9 different companies have already filed for the generic of Geodon, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Geodon's generic
About Geodon
Geodon is a drug owned by Viatris Specialty Llc. It is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis. Geodon uses Ziprasidone Mesylate as an active ingredient. Geodon was launched by Viatris in 2002.
Approval Date:
Geodon was approved by FDA for market use on 21 June, 2002.
Active Ingredient:
Geodon uses Ziprasidone Mesylate as the active ingredient. Check out other Drugs and Companies using Ziprasidone Mesylate ingredient
Treatment:
Geodon is used for managing symptoms of bipolar disorder, neuroleptic diseases, and psychosis.
Dosage:
Geodon is available in powder form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 20MG BASE/VIAL | POWDER | Prescription | INTRAMUSCULAR |